SCOT: tumor sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS)
Authors
Saunders, Mark PIype, Rohan
Kelly, C.
Crosby, J.
Kerr, R.
Harkin, A.
Allan, K.
McQueen, J.
Pearson, S. R.
Cassidy, J.
Medley, L. C.
Raouf, S.
Harrison, M.
Brewster, A.
Rees, C.
Ellis, R.
Thomas, A. L.
Churn, M.
Iveson, T.
Maka, N.
Affiliation
The Christie, Manchester, United Kingdom.Issue Date
2023
Metadata
Show full item recordAbstract
Aim: Patients with loco-regional right-sided colorectal tumors have a worse overall survival (OS). Here we investigate the difference in disease free survival (DFS) between colorectal patients with right and left sided tumors in the SCOT study. Methods: The SCOT study showed 3-months of oxaliplatin-containing adjuvant chemotherapy (OxFp) is non-inferior to 6-months for patients with stage III and high-risk stage II colorectal cancer. We divided the cohort into patients with left and right sided tumors, and evaluated the effect on DFS and the principle 3 versus 6-months analysis. Results: 6088 patients with Stage III/high risk Stage II colorectal cancers were randomized between 27th March 2008 and 29th November 2013 from 244 centers internationally. In February 2017 (3-years FU) information on sidedness was available for 3309 patients (1238 R-sided, 2071 L-sided). Patients with right-sided tumors had a significantly worse DFS (3-year DFS right: 73.3% (se = 1.3%), left: 80.2% (se = 0.9%) HR 1.423 (95% CI 1.237-1.637; P < .0001). Adjusting for T and N-stage reduced the HR to 1.230 (95% CI 1.066-1.420, P = .005). The data did not suggest that sidedness affected the impact of chemotherapy duration on 3-year DFS (R: HR 1.024 [0.831-1.261], L: HR 0.944 [0.783-1.139]). Test for heterogeneity, P = .571. Further sub-set analysis was limited due to cohort size. Conclusions: This is the first study to show that unselected patients with right-sided tumors had a worse DFS compared to left-sided tumors. Tumor sidedness did not impact upon the 3-months versus 6-months comparison in SCOT.Citation
Saunders MP, Iype R, Kelly C, Crosby J, Kerr R, Harkin A, et al. SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS). Clinical colorectal cancer. 2023 Feb 22. PubMed PMID: 36967267. Epub 2023/03/27. eng.Journal
Clinical Colorectal CancerDOI
10.1016/j.clcc.2023.02.005PubMed ID
36967267Additional Links
https://dx.doi.org/10.1016/j.clcc.2023.02.005Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clcc.2023.02.005
Scopus Count
Collections
Related articles
- The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.
- Authors: Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A
- Issue date: 2023 Feb
- Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
- Authors: Saberzadeh-Ardestani B, Foster NR, Lee HE, Shi Q, Alberts SR, Smyrk TC, Sinicrope FA
- Issue date: 2022 Nov
- Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort.
- Authors: Protásio BM, de Castria TB, Natalino R, Mangone FR, Saragiotto DF, Sabbaga J, Hoff PM, Chammas R
- Issue date: 2024 Mar
- 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
- Authors: Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J
- Issue date: 2019 Dec
- The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-line Chemotherapy.
- Authors: Bazarbashi S, Omar AT, Raddaoui L, Badran A, Alzahrani A, Aljubran A, Elhassan T
- Issue date: 2019 Oct 1